Bone Diseases, Metabolic
35
6
7
19
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.9%
1 terminated out of 35 trials
95.0%
+8.5% vs benchmark
26%
9 trials in Phase 3/4
16%
3 of 19 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 19 completed trials
Clinical Trials (35)
Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks
Evaluation of Children With Endocrine and Metabolic-Related Conditions
Evaluation and Treatment of Patients With Connective Tissue Disease
Ultrasound Imaging-based Measurement of Intra-osseous Vascular Response
Bone Properties Following Exercise Induced Changes in Insulin Sensitivity in People With Type 2 Diabetes
Protein Ingestion on BMM Response in Endurance Runners
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
Digital Diagnostics and Intervention Services for Parkinson's Disease
The Impact of Glomerular Disorders on Bone Quality and Strength
The Bone Metabolism Characteristics of Premature Ovarian Insufficiency
Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity
Impact of Glycemic Control on Skeletal Outcomes in Adults With Type 1 Diabetes
The Role of Amylin in Bone Metabolism
Vitamin D and Health Outcomes in Preterm Born Population
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia
Determinants of Bone and Muscle Quality and Strength in Obesity With and Without Diabetes
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients
A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
Patient Activation After DXA Result Notification